{"id":17759,"date":"2023-11-20T09:48:43","date_gmt":"2023-11-20T08:48:43","guid":{"rendered":"https:\/\/actubusinessangels.com\/?p=17759"},"modified":"2023-11-20T09:48:43","modified_gmt":"2023-11-20T08:48:43","slug":"acquisition-dinversago-pharma-par-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/","title":{"rendered":"Acquisition d&#8217;Inversago Pharma par Novo Nordisk"},"content":{"rendered":"\n<p class=\"has-text-align-justify\"><strong><a href=\"https:\/\/www.novonordisk.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Novo Nordisk<\/a><\/strong> entend acqu\u00e9rir <strong><a href=\"https:\/\/inversago.com\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Inversago Pharma<\/a><\/strong>, start-up accompagn\u00e9e par <strong><a href=\"https:\/\/angesquebec.com\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Anges Qu\u00e9bec<\/a><\/strong> et <strong><a href=\"https:\/\/aqccapital.ca\/\" target=\"_blank\" rel=\"noreferrer noopener\">AQC Capital<\/a><\/strong>, afin de mettre au point de nouveaux traitements pour les personnes atteintes d\u2019ob\u00e9sit\u00e9, de diab\u00e8te et d\u2019autres maladies m\u00e9taboliques.<\/p>\n\n\n\n<!--more-->\n\n\n\n<p class=\"has-text-align-justify\">Novo Nordisk A\/S et Inversago Pharma ont annonc\u00e9 que Novo Nordisk avait convenu d\u2019acqu\u00e9rir Inversago pour un montant pouvant aller jusqu\u2019\u00e0 1,075 milliard de dollars US si certaines \u00e9tapes de d\u00e9veloppement et de commercialisation sont franchies. Bas\u00e9e \u00e0 Montr\u00e9al, Inversago Pharma est une soci\u00e9t\u00e9 priv\u00e9e qui met au point des traitements ciblant les r\u00e9cepteurs CB1 pour le traitement potentiel de l\u2019ob\u00e9sit\u00e9, du diab\u00e8te et des complications associ\u00e9es aux maladies m\u00e9taboliques.<\/p>\n\n\n\n<p class=\"has-text-align-justify\">L\u2019acquisition d\u2019Inversago comprend le INV-202, un agoniste inverse du r\u00e9cepteur CB1 \u00e0 prise orale, qui est l\u2019actif principal d\u00e9velopp\u00e9 par la soci\u00e9t\u00e9. Le INV-202 est con\u00e7u pour bloquer de mani\u00e8re pr\u00e9f\u00e9rentielle la prot\u00e9ine r\u00e9ceptrice CB1, laquelle joue un r\u00f4le important dans la r\u00e9gulation du m\u00e9tabolisme et de l\u2019app\u00e9tit, dans les tissus p\u00e9riph\u00e9riques tels que les tissus adipeux, le tractus gastro-intestinal, les reins, le foie, le pancr\u00e9as, les muscles et les poumons.<\/p>\n\n\n\n<p class=\"has-text-align-justify\">Le INV-202 a d\u00e9montr\u00e9 un potentiel prometteur de perte de poids dans un essai de phase 1b et fait actuellement l\u2019objet d\u2019un essai de phase 2 dans le cadre de la maladie r\u00e9nale diab\u00e9tique. D\u2019autres actifs ciblant les maladies m\u00e9taboliques et fibrotiques sont \u00e9galement en cours de d\u00e9veloppement. Novo Nordisk a l\u2019intention d\u2019\u00e9tudier le potentiel que pr\u00e9sente le INV-202 dans les cas d\u2019ob\u00e9sit\u00e9 et de complications li\u00e9es \u00e0 l\u2019ob\u00e9sit\u00e9.<\/p>\n\n\n\n<p class=\"has-text-align-justify\"><em>\u00ab L\u2019acquisition d\u2019Inversago Pharma renforcera davantage notre fili\u00e8re de d\u00e9veloppement clinique en mati\u00e8re d\u2019ob\u00e9sit\u00e9 et de maladies connexes \u00bb<\/em>, a d\u00e9clar\u00e9 Martin Holst Lange, Vice-Pr\u00e9sident ex\u00e9cutif du d\u00e9veloppement chez Novo Nordisk. <em>\u00ab Cette classe prometteuse de m\u00e9dicaments mise au point par l\u2019\u00e9quipe d\u2019Inversago pourrait d\u00e9boucher sur de nouvelles options th\u00e9rapeutiques qui changeraient la vie des personnes atteintes d\u2019une maladie chronique grave et, en particulier, offrir des solutions alternatives ou compl\u00e9mentaires aux personnes touch\u00e9es par l\u2019ob\u00e9sit\u00e9. \u00bb<\/em><\/p>\n\n\n\n<p class=\"has-text-align-justify\">Le r\u00e9cepteur CB1 joue un r\u00f4le important dans la r\u00e9gulation de l\u2019app\u00e9tit et dans d\u2019autres voies cardio-m\u00e9taboliques. Les effets th\u00e9rapeutiques m\u00e9caniques et pr\u00e9cliniques du blocage des r\u00e9cepteurs CB1 p\u00e9riph\u00e9riques sont bien \u00e9tudi\u00e9s pour toute une s\u00e9rie de maladies cardio-m\u00e9taboliques et fibrotiques, ce qui permet d\u2019envisager le traitement potentiel d\u2019un grand nombre de personnes dont les besoins ne sont pas combl\u00e9s \u00e0 l\u2019heure actuelle.<\/p>\n\n\n\n<p class=\"has-text-align-justify\"><em>\u00ab Nous sommes ravis de nous joindre \u00e0 un chef de file mondial dans le domaine de l\u2019ob\u00e9sit\u00e9 et des maladies m\u00e9taboliques \u00bb<\/em>, a d\u00e9clar\u00e9 Fran\u00e7ois Ravenelle, chef de la direction d\u2019Inversago Pharma. <em>\u00ab Nous sommes convaincus que cette alliance contribuera \u00e0 tirer profit du plein potentiel m\u00e9dical de nos inhibiteurs du r\u00e9cepteur CB1 et qu\u2019elle pourrait un jour \u00e9largir les options th\u00e9rapeutiques pour les personnes atteintes du syndrome m\u00e9tabolique, de l\u2019ob\u00e9sit\u00e9 et des complications qui y sont li\u00e9es. Novo Nordisk dispose d\u2019installations de recherche de calibre international, d\u2019une importante pr\u00e9sence mondiale et d\u2019une riche culture de collaboration, en vue de chercher \u00e0 mettre en march\u00e9 nos traitements th\u00e9rapeutiques. \u00bb<\/em><\/p>\n\n\n\n<p class=\"has-text-align-justify\">Inversago emploie 22 personnes, qui continueront de se concentrer sur la r\u00e9ussite des essais en cours et pr\u00e9vus, tout en travaillant en \u00e9troite collaboration avec Novo Nordisk pour faire progresser la technologie d\u2019Inversago dans les futurs essais cliniques. La cl\u00f4ture de l\u2019acquisition est assujettie \u00e0 l\u2019obtention des approbations r\u00e9glementaires applicables ainsi qu\u2019\u00e0 d\u2019autres conditions habituelles et devrait avoir lieu avant la fin de 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk entend acqu\u00e9rir Inversago Pharma, start-up accompagn\u00e9e par Anges Qu\u00e9bec et AQC Capital, afin de mettre au point de nouveaux traitements pour les personnes atteintes d\u2019ob\u00e9sit\u00e9, de diab\u00e8te et d\u2019autres maladies m\u00e9taboliques.<\/p>\n","protected":false},"author":114,"featured_media":17763,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[162,82,60],"tags":[261,112,714,63,924,1116,76],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.7.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acquisition d&#039;Inversago Pharma par Novo Nordisk - France Angels<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acquisition d&#039;Inversago Pharma par Novo Nordisk - France Angels\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk entend acqu\u00e9rir Inversago Pharma, start-up accompagn\u00e9e par Anges Qu\u00e9bec et AQC Capital, afin de mettre au point de nouveaux traitements pour les personnes atteintes d\u2019ob\u00e9sit\u00e9, de diab\u00e8te et d\u2019autres maladies m\u00e9taboliques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\" \/>\n<meta property=\"og:site_name\" content=\"France Angels\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/france.angels\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-20T08:48:43+00:00\" \/>\n<meta name=\"author\" content=\"France Angels\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@franceangels\" \/>\n<meta name=\"twitter:site\" content=\"@franceangels\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"France Angels\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\"},\"author\":{\"name\":\"France Angels\",\"@id\":\"https:\/\/www.franceangels.org\/#\/schema\/person\/23bc1670ad5f0f132d0c3610b1ad2b59\"},\"headline\":\"Acquisition d&#8217;Inversago Pharma par Novo Nordisk\",\"datePublished\":\"2023-11-20T08:48:43+00:00\",\"dateModified\":\"2023-11-20T08:48:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\"},\"wordCount\":668,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.franceangels.org\/#organization\"},\"keywords\":[\"Acquisition\",\"Anges Qu\u00e9bec\",\"AQC Capital\",\"Business Angels\",\"Inversago Pharma\",\"Novo Nordisk\",\"R\u00e9seaux de Business Angels\"],\"articleSection\":[\"2023\",\"D\u00e9veloppement\",\"Les r\u00e9seaux de France Angels\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\",\"url\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\",\"name\":\"Acquisition d'Inversago Pharma par Novo Nordisk - France Angels\",\"isPartOf\":{\"@id\":\"https:\/\/www.franceangels.org\/#website\"},\"datePublished\":\"2023-11-20T08:48:43+00:00\",\"dateModified\":\"2023-11-20T08:48:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.franceangels.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acquisition d&#8217;Inversago Pharma par Novo Nordisk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.franceangels.org\/#website\",\"url\":\"https:\/\/www.franceangels.org\/\",\"name\":\"France Angels\",\"description\":\"F\u00e9d\u00e9ration Nationale des Business Angels\",\"publisher\":{\"@id\":\"https:\/\/www.franceangels.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.franceangels.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.franceangels.org\/#organization\",\"name\":\"France Angels\",\"url\":\"https:\/\/www.franceangels.org\/\",\"sameAs\":[\"https:\/\/linkedin.com\/company\/france-angels\",\"https:\/\/www.youtube.com\/channel\/UC5_t1C5xO9AloWjY4o5ob_Q\",\"https:\/\/facebook.com\/france.angels\/\",\"https:\/\/twitter.com\/franceangels\"],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.franceangels.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.franceangels.org\/wp-content\/uploads\/2022\/04\/Logo-France-Angels.png\",\"contentUrl\":\"https:\/\/www.franceangels.org\/wp-content\/uploads\/2022\/04\/Logo-France-Angels.png\",\"width\":4033,\"height\":1173,\"caption\":\"France Angels\"},\"image\":{\"@id\":\"https:\/\/www.franceangels.org\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.franceangels.org\/#\/schema\/person\/23bc1670ad5f0f132d0c3610b1ad2b59\",\"name\":\"France Angels\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.franceangels.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7686aa9e66054004e747510168483db8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7686aa9e66054004e747510168483db8?s=96&d=mm&r=g\",\"caption\":\"France Angels\"},\"url\":\"https:\/\/www.franceangels.org\/en\/article\/author\/france-angels\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acquisition d'Inversago Pharma par Novo Nordisk - France Angels","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/","og_locale":"en_US","og_type":"article","og_title":"Acquisition d'Inversago Pharma par Novo Nordisk - France Angels","og_description":"Novo Nordisk entend acqu\u00e9rir Inversago Pharma, start-up accompagn\u00e9e par Anges Qu\u00e9bec et AQC Capital, afin de mettre au point de nouveaux traitements pour les personnes atteintes d\u2019ob\u00e9sit\u00e9, de diab\u00e8te et d\u2019autres maladies m\u00e9taboliques.","og_url":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/","og_site_name":"France Angels","article_publisher":"https:\/\/facebook.com\/france.angels\/","article_published_time":"2023-11-20T08:48:43+00:00","author":"France Angels","twitter_card":"summary_large_image","twitter_creator":"@franceangels","twitter_site":"@franceangels","twitter_misc":{"Written by":"France Angels","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#article","isPartOf":{"@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/"},"author":{"name":"France Angels","@id":"https:\/\/www.franceangels.org\/#\/schema\/person\/23bc1670ad5f0f132d0c3610b1ad2b59"},"headline":"Acquisition d&#8217;Inversago Pharma par Novo Nordisk","datePublished":"2023-11-20T08:48:43+00:00","dateModified":"2023-11-20T08:48:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/"},"wordCount":668,"commentCount":0,"publisher":{"@id":"https:\/\/www.franceangels.org\/#organization"},"keywords":["Acquisition","Anges Qu\u00e9bec","AQC Capital","Business Angels","Inversago Pharma","Novo Nordisk","R\u00e9seaux de Business Angels"],"articleSection":["2023","D\u00e9veloppement","Les r\u00e9seaux de France Angels"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/","url":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/","name":"Acquisition d'Inversago Pharma par Novo Nordisk - France Angels","isPartOf":{"@id":"https:\/\/www.franceangels.org\/#website"},"datePublished":"2023-11-20T08:48:43+00:00","dateModified":"2023-11-20T08:48:43+00:00","breadcrumb":{"@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.franceangels.org\/en\/article\/acquisition-dinversago-pharma-par-novo-nordisk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.franceangels.org\/en\/"},{"@type":"ListItem","position":2,"name":"Acquisition d&#8217;Inversago Pharma par Novo Nordisk"}]},{"@type":"WebSite","@id":"https:\/\/www.franceangels.org\/#website","url":"https:\/\/www.franceangels.org\/","name":"France Angels","description":"F\u00e9d\u00e9ration Nationale des Business Angels","publisher":{"@id":"https:\/\/www.franceangels.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.franceangels.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.franceangels.org\/#organization","name":"France Angels","url":"https:\/\/www.franceangels.org\/","sameAs":["https:\/\/linkedin.com\/company\/france-angels","https:\/\/www.youtube.com\/channel\/UC5_t1C5xO9AloWjY4o5ob_Q","https:\/\/facebook.com\/france.angels\/","https:\/\/twitter.com\/franceangels"],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.franceangels.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.franceangels.org\/wp-content\/uploads\/2022\/04\/Logo-France-Angels.png","contentUrl":"https:\/\/www.franceangels.org\/wp-content\/uploads\/2022\/04\/Logo-France-Angels.png","width":4033,"height":1173,"caption":"France Angels"},"image":{"@id":"https:\/\/www.franceangels.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.franceangels.org\/#\/schema\/person\/23bc1670ad5f0f132d0c3610b1ad2b59","name":"France Angels","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.franceangels.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7686aa9e66054004e747510168483db8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7686aa9e66054004e747510168483db8?s=96&d=mm&r=g","caption":"France Angels"},"url":"https:\/\/www.franceangels.org\/en\/article\/author\/france-angels\/"}]}},"_links":{"self":[{"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/posts\/17759"}],"collection":[{"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/users\/114"}],"replies":[{"embeddable":true,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/comments?post=17759"}],"version-history":[{"count":0,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/posts\/17759\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/media?parent=17759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/categories?post=17759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.franceangels.org\/en\/wp-json\/wp\/v2\/tags?post=17759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}